| Net Cash Provided by (Used in) Operating Activities |
-121 |
USD |
-1.6% |
Q3 2025 |
Q3 2025 |
| Net Cash Provided by (Used in) Financing Activities |
0 |
USD |
|
Q3 2025 |
Q3 2025 |
| Common Stock, Shares Authorized |
100,000,000 |
shares |
0% |
Q3 2025 |
Q3 2025 |
| Common Stock, Shares, Issued |
6,893,056 |
shares |
|
Q3 2025 |
Q3 2025 |
| Common Stock, Par or Stated Value Per Share |
0 |
USD/shares |
0% |
Q3 2025 |
Q3 2025 |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect |
-121 |
USD |
-1.6% |
Q3 2025 |
Q3 2025 |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
2,609 |
USD |
-18.4% |
Q3 2023 |
Q3 2023 |
| Deferred Tax Assets, Valuation Allowance |
44,044,236 |
USD |
-7.6% |
Q4 2024 |
Q3 2025 |
| Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent |
0.21 |
pure |
0% |
Q3 2025 |
Q3 2025 |
| Deferred Tax Assets, Gross |
44,044,236 |
USD |
-7.6% |
Q4 2024 |
Q3 2025 |
| Deferred Income Tax Expense (Benefit) |
0 |
USD |
|
Q1 2024 |
Q1 2024 |
| Deferred Tax Assets, Operating Loss Carryforwards |
3,243,806 |
USD |
-6.4% |
Q4 2024 |
Q3 2025 |
| Deferred Federal Income Tax Expense (Benefit) |
0 |
USD |
|
Q1 2024 |
Q1 2024 |
| Unrecognized Tax Benefits |
0 |
USD |
|
Q4 2024 |
Q3 2025 |
| Additional Paid in Capital |
176,770,722 |
USD |
0% |
Q3 2025 |
Q3 2025 |
| Deferred Tax Assets, Net of Valuation Allowance |
0 |
USD |
|
Q4 2024 |
Q3 2025 |
| Deferred State and Local Income Tax Expense (Benefit) |
0 |
USD |
|
Q1 2024 |
Q1 2024 |